Online citations, reference lists, and bibliographies.
← Back to Search

Synthesis And Biological Evaluation Of Dimeric RGD Peptide-paclitaxel Conjugate As A Model For Integrin-targeted Drug Delivery.

X. Chen, C. Plasencia, Y. Hou, N. Neamati
Published 2005 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Targeting drugs to receptors involved in tumor angiogenesis is a novel and promising approach to improve cancer treatment. In this study, we evaluated the antitumor activity of paclitaxel (PTX) conjugated with a bicyclic peptide E[c(RGDyK)](2) (RGD) in a metastatic breast cancer cell line (MDA-MB-435). The cyclic RGD peptide selectively binds to alpha(v) integrin receptors that are highly expressed in metastatic cancer cells. PTX, an antimicrotubule agent, is a potent antitumor agent commonly used in the treatment of advanced metastatic breast cancer. The in vitro results showed that RGD peptide inhibited cell cycle proliferation by arresting cells in G(0)/G(1)-phase. The PTX-RGD conjugate inhibited cell proliferation with activity comparable to that observed for paclitaxel, both of which were mediated by an arrest of G(2)/M-phase of the cell cycle followed by apoptosis. Although the PTX-RGD conjugate showed slightly decreased integrin binding affinity than the unconjugated peptide, it indicated integrin specific accumulation in vivo. (125)I-Labeled PTX-RGD showed highest tumor uptake at 2 h postinjection (2.72 +/-0.16%ID/g) and best tumor/background contrast after 4 h postinjection. Our results demonstrate the potential of tumor-targeted delivery of paclitaxel based on the specific recognition of cell adhesion molecule alpha(v)beta(3) integrin to reduce toxicity and enhance selective killing of cancer cells.
This paper references
10.1016/0065-2571(84)90007-4
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
T. Chou (1984)
10.1016/J.MIBIO.2004.06.004
MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides.
X. Chen (2004)
10.1002/1521-3773(20021018)41:20<3767::AID-ANIE3767>3.0.CO;2-T
The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction.
Kay-E Gottschalk (2002)
10.1038/nrd819
Angiogenesis modulation in cancer research: novel clinical approaches
M. Cristofanilli (2002)
Cilengitide targeting
P. A. Burke (2001)
10.1038/nm0902-918
A reevaluation of integrins as regulators of angiogenesis
R. Hynes (2002)
10.1162/1535350041464892
Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide.
X. Chen (2004)
10.1021/BC034170N
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.
R. Haubner (2004)
Synthesis and biological evaluation of PTX-C225 conjugate as a model for targeted drug delivery
A. Safavy (2003)
10.1021/BC000146N
(90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy.
S. Liu (2001)
10.1021/JM001065F
Novel peptide conjugates for tumor-specific chemotherapy.
M. Langer (2001)
Synthesis of congeners and prodrugs
H. M. Deutsch (1989)
10.1101/GAD.10.1.1
Life, death, and the pursuit of apoptosis.
E. White (1996)
18F and 64Cu-labeled RGD peptide for imaging breast cancer in mice with microPET
X. Chen (2004)
10.1038/sj.bjc.6600141
Inhibition of the alpha-ν integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo
M. A. Buerkle (2002)
64Cu-labeling and PET imaging of brain tumor angiogenesis
X. Chen (2004)
10.1158/0008-5472.CAN-04-1956
In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts
X. Chen (2004)
10.1002/(SICI)1097-0320(19970701)28:3<253::AID-CYTO10>3.0.CO;2-O
Correlated flow cytometric analysis of terminal events in apoptosis reveals the absence of some changes in some model systems.
T. Frey (1997)
10.1023/A:1020312220968
Tumor Vasculature Directed Drug Targeting: Applying New Technologies and Knowledge to the Development of Clinically Relevant Therapies
G. Molema (2004)
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
M. Janssen (2002)
vâ3 integrin binding peptides in a nude mouse model
J. P. Xiong (2002)
10.1002/CHEM.200204304
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation.
Georgette Thumshirn (2003)
10.1016/s0065-230x(08)60058-5
Tumor angiogenesis.
J. Folkman (1985)
Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages.
V. Fadok (1992)
Emission Tomography F-labeled RGD-containing Glycopeptide and Positron 18 Integrin Expression Using 3 β v α Noninvasive Imaging of Updated Version
R. Haubner (2001)
Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor.
C. Kumar (1997)
10.1097/00001622-199012000-00010
Treatment of metastatic breast cancer.
N. Robert (1990)
10.1007/s00259-003-1452-2
MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide
X. Chen (2003)
10.1186/1471-2407-4-35
The influence of tumor size and environment on gene expression in commonly used human tumor lines
M. Gieseg (2004)
18F-labeled PEGylated RGD peptide
Y. Hou (2004)
10.1152/AJPCELL.1995.269.1.C110
Arg-Gly-Asp peptide increases endothelial hydraulic conductivity: comparison with thrombin response.
R. L. Qiao (1995)
10.1126/SCIENCE.1064535
Crystal Structure of the Extracellular Segment of Integrin αVβ3
J. Xiong (2001)
10.1038/sj.gt.3301817
Combined effects on tumor growth and metastasis by anti-estrogenic and antiangiogenic therapies in MMTV-neu mice
M. Sacco (2002)
10.1016/J.NUCMEDBIO.2003.10.002
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.
X. Chen (2004)
10.1023/B:CLIN.0000024763.69809.64
A small molecule antagonist of the αvβ3 integrin suppresses MDA-MB-435 skeletal metastasis
J. Harms (2004)
PEGylated RGD peptide : 64 Cu - labeling and PET imaging of brain tumor angiogenesis
X. Chen (2004)
Rvâ3 blocks human breast cancer growth and angiogenesis in human skin
M. A. Buerkle (1995)
10.1038/nm0603-685
Molecular regulation of vessel maturation
R. Jain (2003)
10.1126/SCIENCE.1069040
Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand
J. Xiong (2002)
10.1172/JCI118227
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
P. Brooks (1995)
Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts
P. Burke (2002)
10.1634/THEONCOLOGIST.6-2-133
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
F. Esteva (2001)
10.1097/00006123-200101000-00026
Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist
T. MacDonald (2001)
10.1016/J.NUCMEDBIO.2003.07.003
Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation.
X. Chen (2004)
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.
P. Brooks (1994)
Rvâ3 receptor
M. A. Gieseg (1997)
Alphav integrins mediate adhesion and migration of breast carcinoma cell lines.
N. C. Wong (1998)
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
M. Alley (1988)
10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors.
M. Mammen (1998)
10.1038/nm0901-987
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
R. Jain (2001)
10.7326/0003-4819-93-4-651_3
Cancer chemotherapy handbook
R. Dorr (1980)
10.1021/JM00124A011
Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity.
H. Deutsch (1989)



This paper is referenced by
10.1002/ardp.201300231
Oxadiazoles as Privileged Motifs for Promising Anticancer Leads: Recent Advances and Future Prospects
I. Khan (2014)
10.1016/j.ejmech.2016.02.009
Dihydropyrazole derivatives as telomerase inhibitors: Structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo.
Y. Wang (2016)
10.4236/ABC.2013.32028
Importance of integrin receptors in the field of pharmaceutical & medical science
S. Goswami (2013)
10.1002/wnan.4
Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents.
R. Juliano (2009)
10.7150/thno.14338
Preliminary Therapy Evaluation of 225Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization
Darpan N Pandya (2016)
10.1021/mp400096z
Multivalency of non-peptide integrin αVβ3 antagonist slows tumor growth.
Yoo-Shin Kim (2013)
10.1021/bc300164t
Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.
M. Pilkington-Miksa (2012)
10.1517/13543784.14.12.1475
Targeting integrins for the control of tumour angiogenesis
A. Akalu (2005)
10.1016/j.biomaterials.2014.08.019
Development and in vitro assessment of enzymatically-responsive poly(ethylene glycol) hydrogels for the delivery of therapeutic peptides.
Amy H. Van Hove (2014)
10.1016/J.CHEMBIOL.2005.11.007
Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture.
M. Flenniken (2006)
10.1117/12.648105
Synthesis and evaluation of two NIR fluorescent cyclic RGD penta-peptides for targeting integrins
Y. Ye (2006)
10.1007/s10989-008-9163-y
Binding and Uptake of RGD-Containing Ligands to Cellular αvβ3 Integrins
Sonya Cressman (2008)
10.1161/CIRCULATIONAHA.107.733220
Monitoring of the Biological Response to Murine Hindlimb Ischemia With 64Cu-Labeled Vascular Endothelial Growth Factor-121 Positron Emission Tomography
J. Willmann (2008)
10.1002/med.20225
Peptide‐mediated targeted drug delivery
S. Majumdar (2012)
10.1038/srep19800
Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide
Q. Zhang (2016)
10.1016/j.bmc.2011.06.061
Oxadiazole derivatives containing 1,4-benzodioxan as potential immunosuppressive agents against RAW264.7 cells.
J. Sun (2011)
10.1016/j.bmcl.2011.03.066
Design and synthesis of N-phenylacetyl (sulfonyl) 4,5-dihydropyrazole derivatives as potential antitumor agents.
Xin-Hua Liu (2011)
10.7150/THNO/V01P0211
Integrin Targeted Delivery of Gene Therapeutics
R. Juliano (2011)
10.1002/stem.3069
Engineered stem cells targeting multiple cell surface receptors in tumors
Sanam L Kavari (2019)
DDDT_A_219489 3753..3772
Moraima Morales-Cruz (2019)
10.1002/9781118260005.CH8
Recent Progress in the Chemistry and Biology of Paclitaxel (TaxolTM) and Related Taxanes
J. Qi (2012)
10.1002/jbm.a.32922
Bone marrow stromal cells cultured on poly (lactide-co-glycolide)/nano-hydroxyapatite composites with chemical immobilization of Arg-Gly-Asp peptide and preliminary bone regeneration of mandibular defect thereof.
Y. Huang (2010)
10.1016/j.jconrel.2009.12.020
Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
C. Zhan (2010)
10.3109/1061186X.2010.542244
Cyclic RGD-poly(ethylene glycol)-polyethyleneimine is more suitable for glioblastoma targeting gene transfer in vivo
C. Zhan (2011)
Desintegrinas de Bothrops alternatus: biologia molecular, estudos in vitro, in vivo e bioinformática estrutural.
O. H. Ramos (2005)
10.1007/978-3-662-49231-4_10-1
Preparation of Functional Vincristine Liposomes for Treatment of Invasive Breast Cancer
Fan Zeng (2018)
10.1021/bc8000485
Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity.
H. Lee (2008)
10.1080/1061186X.2017.1323334
Design of multifunctional liposome-quantum dot hybrid nanocarriers and their biomedical application
Wenjing Qu (2017)
10.1002/ardp.201800379
Design, synthesis and biological evaluation of peptide‐NSAID conjugates for targeted cancer therapy
Bahareh Shokri (2019)
10.1533/9780857096449.2.236
Nanoparticulate targeted drug delivery using peptides and proteins
H. Santos (2012)
10.1002/APP.42772
Polyphosphoester‐based paclitaxel complexes
Violeta Mitova (2015)
10.1016/j.biomaterials.2012.12.049
Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel.
Xinyi Jiang (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar